Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ADMG let's get the ball rolling...
RIBT nice new years resolution pop to eat smarter
FNMA so what's brewing here this thing has almost gotten slashed in half YTD, is this a good time to buy? What's the reason for the recent drubbing?
NWMH nice DD thanks for taking the time to report in on this blatant and inexcusable fraud...
Welcome to SJB (Short Junk Bonds).
Thank you for your DD
HKFI you got your wish, now what? What's brewing here, trading like it's going bankrupt.
hallo to all, XLITsters ;)
MYXY how high will they try to wash this garbage before the fadeout?
DHRM kaboom
yeah nice move
UBIQ the pump and dump crew can't move this garbage?
IHRT ouch huge miss for the dittoheads, as co. reports -$2.63 earnings per share for the quarter, missing analyst consensus estimates of -$1.00 by $1.63.
MJMI and there goes the bid.
CIBR Top Holdings (as of 11/4/2015)
Qihoo 360 Technology Co. Ltd. (ADR) 6.55%
Cisco Systems, Inc. 6.38%
Palo Alto Networks, Inc. 5.88%
NXP Semiconductors N.V. 5.48%
LifeLock, Inc. 4.96%
FireEye, Inc. 4.47%
Proofpoint, Inc. 3.69%
Qualys, Inc. 3.65%
Juniper Networks, Inc. 3.57%
Imperva, Inc. 3.52%
EURI nice $volume breakout, how high will these Romanians try to paint it?
New $2.6B deal between Boston-area biotechs a first for gene editing
Cambridge startup CRISPR Therapeutics is getting $105 million up front, and as much as $2.6 billion in coming years, in a new partnership with Vertex Pharmaceuticals that CRISPR CEO Rodger Novak called “the first really big deal” in the burgeoning field of gene editing.
CRISPR, a privately-held company — which, coincidentally, just moved into a building formerly occupied by Vertex(Nasdaq: VRTX) over the summer — said the deal could help develop cures for diseases including sickle cell and cystic fibrosis. While all research in gene editing — treatments designed to fix genes that cause disease — is still very early stage, Nozak said in an interview today it’s “very likely” that a treatment for sickle cell could begin human trials sometime before the end of the four-year research agreement.
If successful, the collaboration could result in a method to correct the underlying gene mutations that cause cystic fibrosis. While the approach is yet unproven, the hope is that a one-time treatment with gene editing would render the drugs now marketed by Vertex for that disease — including Kalydeco and Orkambi — obsolete.
“The main interest of both Vertex and ours is to help patients with cystic fibrosis. Their therapies are helping patients tremendously now ... but there is room for improvement,” said Novak.
Currently, almost all the treatments in development at Vertex are small-molecule, or pill-based, drugs, so the CRISPR deal represents a new type of research for the 30-year-old company. Vertex will have the option to exclusively license up to six potential treatments (including for cystic fibrosis), and for most of them it would pay for all development and commercialization costs — up to $420 million each, plus sales royalties. The only exception would be in sickle cell, where CRISPR will pay half the R&D costs and would lead any commercialization efforts.
The deal appears to be exactly the kind touted as a benefit of Cambridge’s life sciences cluster, where two local companies decide to join forces on a project that would advance human health. Novak said that the physical proximity of the two companies (Vertex is in South Boston; CRISPR is in East Cambridge) played a part, but was also helped by an existing relationship between the top scientists at both companies, Vertex’s David Altshuler and CRISPR’s Bill Lundberg.
The focus on sickle cell makes CRISPR a potential competitor with another big local biotech, bluebird bio (Nasdaq: BLUE). Cambridge-based bluebird has a promising gene therapy treatment (which seeks to replace, rather than edit, a faulty gene) in early-stage clinical development to address the disease. Novak said in this disease, gene editing has the potential to be as effective as gene therapy, but with fewer side effects, though he added that the technology still needs to prove it works.
CRISPR is one of three local biotech firms now pursuing gene editing using a technique known as CRISPR/Cas9, which allows for multiple cuts, or “edits,” to a single gene. Cambridge-based Editas Medicine made a deal in May potentially worth more than $700 million with Seattle-based Juno Therapeutics (Nasdaq: JUNO), which last year held the sector’s biggest initial public offering of of $265 million. Cambridge-based Intellia Therapeutics, which has yet to announce a major deal with a more established company, just got a $70 million investment last month.
http://www.bizjournals.com/boston/blog/bioflash/2015/10/new-2-6b-deal-between-boston-area-biotechs-a.html
RGNX no bid support, too early still, listed VC...
Blueprint Medicines Corp's (BPMC) Lock-Up Period Set To End on October 27th
Nice looking setup Pistol Pete.
I like the name and think the WS crowd will also want to own this iconic luxury brand. I'll be a buyer despite the tepid IPO market. Good luck to you!
Nice move in KIRI, not surprising given the promo. If the numbers are to be believed, this co. has been executing on the top and bottom line. But they are Chinese, so you can't really trust them. Caution is warranted.
Ferrari next week! Not the best timing with the VW scandal looming and overall weak IPO market. Hopefully they open it at or below the expected range of $48-52.
Ahh Extended Duration Treasuries. I like it as a hedge against falling markets. Pays a decent dividend too!
Welcome to TRHF- where you too can own a piece of a worthless Chinese shell w/ market cap of $4.7B.
Nice to see you back here posting on iHub Mr. Rumball!
Low .70s where's that dumbfuck supertrades when you need him?
O/S was 16.27M shares, and after the secondary offering of 14.8M shares new O/S will be 31.07M shares which is 90% dilution unfortunately. Not bashing just stating facts- the fund raising is necessary to keep the company solvent and advance trials. Even 31M is a very low float.
Nice to see Sheff taking a cautious approach...
They're still in preclinical trials aren't they? Getting all the way to phase 2 is pipe dream with that kinda cash... Sorry don't get me wrong I'm as bullish on this stock long term as the next guy, and I do think there are great possibilities here but I feel the co. needs to step it up and stop the bleeding. Keep in mind we're looking at around 90% dilution of shares, however you want to slice and dice it- private placement secondary offering whatever, 90% dilution at the end of the day.
NMUS secondary offering of 14.8M shares. Wow they just did a pvt placement less than a month ago- they don't seem to have much regard for shareholders do they? Maybe they're sabotaging the stock to attract a JV/M&A at lower prices?
Sure you did, you just got in yesterday before the close and sold the high of day as usual no doubt.
No need to pump bro, will collapse soon enough with or without you.
PSUN this retailer has already collapsed. Do not buy this stock! Soon to be bankrupt and delisted.
AHCP now now guys no need to pump so aggressively
I'd rather buy BRK.A ;)
http://investorshub.advfn.com/Berkshire-Hathaway-Inc-BRKA-6071/